Scientists test drug combo to fight tough blood cancer
NCT ID NCT04802161
Summary
This study is testing if adding a drug called pomalidomide to standard chemotherapy works better for adults newly diagnosed with a specific, harder-to-treat type of acute myeloid leukemia (AML). About 50 participants will be randomly assigned to receive either the standard chemo or the standard chemo plus pomalidomide. The main goal is to see if the new combination leads to more patients having their cancer go into remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
NYP/Weill Cornell Medical Center
New York, New York, 10065, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, Ohio, 45219, United States
-
University of Cincinnati Cancer Center-West Chester
West Chester, Ohio, 45069, United States
-
University of Kansas Cancer Center
Kansas City, Kansas, 66160, United States
-
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, 66205, United States
-
University of Virginia Cancer Center
Charlottesville, Virginia, 22908, United States
-
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157, United States
Conditions
Explore the condition pages connected to this study.